![]() |
Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-p
Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.
More... |
| All times are GMT -7. The time now is 07:50 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021